Utility of GnRH-agonists for Fertility Preservation in Women With Operable Breast Cancer: Is It Protective?
Breast cancer is the most common type of malignancy in reproductive-age women. Breast cancer chemotherapy is associated with premature ovarian failure, infertility and negative psychosocial effects related to these reproductive changes. As a result of this, fertility preservation becomes highly critical in this group of women. Besides the fertility preservation methods that utilize assisted reproductive technologies such as embryo, oocyte, and ovarian tissue cryopreservation, another suggested strategy for fertility preservation is suppression of ovarian ovulatory function by gonadotropin-releasing hormone agonist (GnRHa) administration before and during chemotherapy. However, both the efficacy and safety of GnRH agonists for prevention of ovarian damage are unproven and the preponderance of evidence indicates that this is an ineffective strategy. This review details the most recent information and studies on this controversial topic.
Laboratory of Molecular Reproduction & Fertility Preservation, Obstetrics and Gynecology, New York Medical College, Valhalla, NY ; Innovation Institute for Fertility Preservation and IVF, New York, NY.
Giuliano
G
Bedoschi
Laboratory of Molecular Reproduction & Fertility Preservation, Obstetrics and Gynecology, New York Medical College, Valhalla, NY ; Innovation Institute for Fertility Preservation and IVF, New York, NY.
Volkan
V
Turan
Laboratory of Molecular Reproduction & Fertility Preservation, Obstetrics and Gynecology, New York Medical College, Valhalla, NY ; Innovation Institute for Fertility Preservation and IVF, New York, NY.
Kutluk
K
Oktay
Breast cancer; Chemotherapy; Clinical trials; Fertility preservation; GnRH agonist; Gonadal damage; Gonadal suppression